679 related articles for article (PubMed ID: 23410825)
1. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
[TBL] [Abstract][Full Text] [Related]
2. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ
Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y
Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135
[TBL] [Abstract][Full Text] [Related]
4. [DNA repair pathways and non-small cell lung cancer: clinical perspectives].
Olaussen KA; Planchard D; Adam J; Soria JC
Bull Cancer; 2011 Mar; 98(3):305-22. PubMed ID: 21459711
[TBL] [Abstract][Full Text] [Related]
5. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.
Cheng H; Zhang Z; Borczuk A; Powell CA; Balajee AS; Lieberman HB; Halmos B
Carcinogenesis; 2013 Apr; 34(4):739-49. PubMed ID: 23275151
[TBL] [Abstract][Full Text] [Related]
6. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer.
Shiraishi K; Kohno T; Tanai C; Goto Y; Kuchiba A; Yamamoto S; Tsuta K; Nokihara H; Yamamoto N; Sekine I; Ohe Y; Tamura T; Yokota J; Kunitoh H
J Clin Oncol; 2010 Nov; 28(33):4945-52. PubMed ID: 20940192
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.
Michels J; Vitale I; Senovilla L; Enot DP; Garcia P; Lissa D; Olaussen KA; Brenner C; Soria JC; Castedo M; Kroemer G
Cell Cycle; 2013 Mar; 12(6):877-83. PubMed ID: 23428903
[TBL] [Abstract][Full Text] [Related]
8. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer.
Postel-Vinay S; Bajrami I; Friboulet L; Elliott R; Fontebasso Y; Dorvault N; Olaussen KA; André F; Soria JC; Lord CJ; Ashworth A
Oncogene; 2013 Nov; 32(47):5377-87. PubMed ID: 23934192
[TBL] [Abstract][Full Text] [Related]
9. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
Olaussen KA; Mountzios G; Soria JC
Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses.
Pierceall WE; Olaussen KA; Rousseau V; Brambilla E; Sprott KM; Andre F; Pignon JP; Le Chevalier T; Pirker R; Jiang C; Filipits M; Chen Y; Kutok JL; Weaver DT; Ward BE; Soria JC
Ann Oncol; 2012 Sep; 23(9):2245-2252. PubMed ID: 22269178
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin resistance associated with PARP hyperactivation.
Michels J; Vitale I; Galluzzi L; Adam J; Olaussen KA; Kepp O; Senovilla L; Talhaoui I; Guegan J; Enot DP; Talbot M; Robin A; Girard P; Oréar C; Lissa D; Sukkurwala AQ; Garcia P; Behnam-Motlagh P; Kohno K; Wu GS; Brenner C; Dessen P; Saparbaev M; Soria JC; Castedo M; Kroemer G
Cancer Res; 2013 Apr; 73(7):2271-80. PubMed ID: 23554447
[TBL] [Abstract][Full Text] [Related]
12. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.
Felip E; Rosell R
Expert Rev Mol Diagn; 2007 May; 7(3):261-8. PubMed ID: 17489733
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of DNA repair gene polymorphisms and survival in patients with early stage non-small-cell lung cancer.
Kim M; Kang HG; Lee SY; Lee HC; Lee EB; Choi YY; Lee WK; Cho S; Jin G; Jheon HS; Son JW; Lee MH; Jung DK; Cha SI; Kim CH; Kang YM; Kam S; Jung TH; Jheon S; Park JY
Cancer Sci; 2010 Nov; 101(11):2436-42. PubMed ID: 20731661
[TBL] [Abstract][Full Text] [Related]
15. MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.
Levallet G; Dubois F; Fouret P; Antoine M; Brosseau S; Bergot E; Beau-Faller M; Gounant V; Brambilla E; Debieuvre D; Molinier O; Galateau-Sallé F; Mazieres J; Quoix E; Pujol JL; Moro-Sibilot D; Langlais A; Morin F; Westeel V; Zalcman G
Oncotarget; 2017 Jan; 8(3):4313-4329. PubMed ID: 28008145
[TBL] [Abstract][Full Text] [Related]
16. Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
Boerner JL; Nechiporchik N; Mueller KL; Polin L; Heilbrun L; Boerner SA; Zoratti GL; Stark K; LoRusso PM; Burger A
PLoS One; 2015; 10(3):e0119614. PubMed ID: 25774912
[TBL] [Abstract][Full Text] [Related]
17. Transcriptomics reveals
Stolzenburg LR; Ainsworth B; Riley-Gillis B; Pakozdi T; Ammar A; Ellis PA; Wilsbacher JL; Ramathal CY
Oncotarget; 2022; 13():1-12. PubMed ID: 35018214
[TBL] [Abstract][Full Text] [Related]
18. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
[TBL] [Abstract][Full Text] [Related]
19. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
20. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2.
Ko JC; Su YJ; Lin ST; Jhan JY; Ciou SC; Cheng CM; Chiu YF; Kuo YH; Tsai MS; Lin YW
Lung Cancer; 2010 Aug; 69(2):155-64. PubMed ID: 19962780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
